Press Release MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update 2 hours ago
Press Release MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia Jul 27